Treatment Use Study for Advanced Melanoma.

• Conditions: Advanced Unresectable Melanoma

• Registration Number: NCT00584493
• Lead Sponsor: Pfizer

Brief Summary

The purpose of this study is to provide access to CP-675,206 for patients with advanced unresectable melanoma and who have the potential to gain benefit from this treatment and who are not eligible for participation in other CP-675,206 studies.

Detailed Description

This is an expanded access trial that canceled prior to enrolling patients.

Study Timeline

• Study First Submitted: 2007-12-21
• Study First Submitted QC: 2007-12-21
• Study First Posted: 2008-01-02
• Study Start: 2008-05
• Status Verified: 2009-12
• Last Update Submitted: 2009-12-11
• Last Update Posted: 2009-12-14

Recruitment & Eligibility

• Status: NO_LONGER_AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Advanced melanoma with life expectancy of at least 6 months.
• Melanoma must be considered unresectable.
• Patients with stable, treated brain mets must be stable clinically and radiographically and off steroids for at least one month.

Exclusion Criteria

• Patients must not be eligible for participation in any ongoing CP-675,206 clinical studies currently open for enrollment.
• History of chronic inflammatory or autoimmune disease.
• History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, active colitis, history of diverticulitis.

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified